Puma Biotechnology (PBYI) Capital Expenditures Growth (3y) (2014 - 2023)
Puma Biotechnology (PBYI) Capital Expenditures Growth (3y) (2014 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 16.27% |
| 10 | Puma Biotechnology | 407.78 Mn | 369.49 Mn | 34.39 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 4.17% |
| Sep 30, 2023 | -49.83% |
| Dec 31, 2020 | 27.83% |
| Sep 30, 2020 | -58.51% |
| Jun 30, 2020 | -28.56% |
| Mar 31, 2020 | -52.85% |
| Dec 31, 2018 | -103.61% |
| Sep 30, 2018 | -26.37% |
| Jun 30, 2018 | 40.96% |
| Mar 31, 2018 | -54.86% |
| Dec 31, 2017 | -72.79% |
| Jun 30, 2017 | -57.74% |
| Mar 31, 2017 | 214.14% |
| Dec 31, 2016 | 89.69% |
| Jun 30, 2016 | 164.47% |
| Mar 31, 2016 | -37.82% |
| Dec 31, 2015 | -27.37% |
| Sep 30, 2015 | 56.06% |
| Jun 30, 2015 | -93.32% |
| Mar 31, 2015 | 32.50% |